The Disease That Turns You Into a Statue Just Got Its Newest Enemy

Fewer patients on the drug developed new bone lesions at all. And in the open-label extension, where everyone got the drug (including patients who'd been on placebo), no new bone lesions were observed among those who continued or crossed over.

The wrinkle? The study's primary endpoint, which measured the proportion of patients who developed any new bone lesions at Week 24, reportedly didn't hit traditional statistical significance. Some market watchers flagged this. But the sheer magnitude of the volume data, combined with the safety profile and the devastating unmet need, gave the FDA enough to grant approval under Priority Review.

It's worth noting the tolerability looked clean: during the 24-week controlled period, no patients discontinued or reduced their dose because of side effects.

Not the First, but Possibly the Best Shot

Sharp-eyed readers might recall that palovarotene (brand name Sohonos) was approved for FOP back in 2023, making it technically the first FDA-approved treatment. So calling Atebrioz a landmark isn't quite right in a "first-ever" sense; it's the second approved option.

But for the FOP community, having two treatments with different mechanisms is arguably more important than being first. FOP manifests differently from patient to patient. Some have frequent flares; others have slow, steady progression. More options mean more flexibility, as IFOPA Executive Director Michelle Davis noted, and that flexibility matters enormously when you're managing a lifelong, unpredictable disease.

The IFOPA (International FOP Association) highlighted the 63 patients who participated in the PROGRESS trial, a remarkable number given how few people have this condition worldwide. Global estimates suggest there may be only about 11,000 FOP patients total, though many are likely undiagnosed, especially in regions with limited genetic testing.

The Business of Ultra-Rare

So what does this mean for Mirum's bottom line?

Analyst Jonathan Wolleben at Citizens pegged the estimated price at roughly $750,000 per year, with peak worldwide sales of about $150 million. Mirum said it would announce its official price at launch, which is expected in October.

Those numbers might sound modest compared to blockbuster oncology drugs. But in ultra-rare disease, the math works differently. You're treating hundreds of patients, not hundreds of thousands. The price per patient is high because the development costs are spread across a tiny population, and payers generally accept premium pricing for serious conditions with no alternatives.

Mirum licensed worldwide rights to zilurgisertib from Incyte, so the commercial story is theirs to write. The next chapter depends on real-world factors: how quickly insurers approve coverage, how many patients can be identified and started on therapy, and whether the drug's benefits hold up over years of use.

Why This One Hits Different

It's easy to be cynical about rare disease approvals. The patient populations are small. The trials are underpowered by traditional standards. The prices make people's eyes water.

But FOP is the kind of disease that reminds you why this industry exists. Kids who seem perfectly healthy start growing bone where there should be muscle. A minor bump or a flu shot can trigger a flare that permanently locks a joint. There's no going back once the bone forms.

For 63 brave patients who enrolled in a clinical trial, and for the thousands of others watching from around the world, a once-daily tablet that reduced new bone formation by over 99% isn't just a statistic. It's the difference between a body that keeps betraying you and one that might, finally, slow down.

Mirum's Atebrioz won't cure FOP. Nobody's claiming it will. But for a community that spent most of its existence with zero approved therapies, having a second weapon in the arsenal is something worth celebrating.

The $3.9 Million Shot That Could Save Kids With No Other Options

For decades, families with Sanfilippo syndrome were told to take their kids home and love them. Now a $3.9 million gene therapy from Ultragenyx is the first FDA-approved treatment for this fatal childhood brain disease, and it's part of a wave that's reshaping rare disease medicine.